Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.121
Buy
RSI(14)
69.764
Neutral
STOCH(KDJ)(9,3,3)
67.375
Sell
ATR(14)
0.177
High Vlolatility
CCI(14)
122.691
Buy
Williams %R
38.017
Buy
TRIX(12,20)
1.842
Buy
StochRSI(14)
0.000
Sell
Marker Therapeutics Inc
MRKR2.000USD
-0.070-3.38%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
33.40MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Marker Therapeutics Inc
Currency: USD Updated: 2026-01-09Key Insights
Marker Therapeutics Inc's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 46 out of 396 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.03.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Marker Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Marker Therapeutics Inc Highlights
StrengthsRisks
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 87.59% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.59M.
Fairly Valued
The company’s latest PE is -1.71, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.45M shares, decreasing 18.06% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 299.78K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 6.29.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
9.025
Target Price
+404.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-01-09The current financial score of Marker Therapeutics Inc is 8.39, ranking 48 out of 396 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.23M, representing a year-over-year decrease of 35.99%, while its net profit experienced a year-over-year decrease of 13.41%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.17
Operational Efficiency
10.00
Growth Potential
6.59
Shareholder Returns
7.19
Marker Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-01-09The current valuation score of Marker Therapeutics Inc is 8.40, ranking 47 out of 396 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.71, which is -87.28% below the recent high of -0.22 and -401.29% above the recent low of -8.56.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 46/396
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-01-09The current earnings forecast score of Marker Therapeutics Inc is 8.00, ranking 165 out of 396 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 12.50 and a low of 4.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
9.025
Target Price
+404.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
536
Total
6
Median
6
Average
Company name
Ratings
Analysts
Marker Therapeutics Inc
MRKR
3
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
26
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Beigene Ltd
ONC
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-01-09The current price momentum score of Marker Therapeutics Inc is 8.92, ranking 59 out of 396 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.56 and the support level at 1.35, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.982
Buy
MA10
1.736
Buy
MA20
1.545
Buy
MA50
1.271
Buy
MA100
1.129
Buy
MA200
1.238
Buy
Institutional Confidence
Currency: USD Updated: 2026-01-09The current institutional shareholding score of Marker Therapeutics Inc is 3.00, ranking 196 out of 396 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 20.70%, representing a quarter-over-quarter decrease of 22.25%. The largest institutional shareholder is The Vanguard, holding a total of 299.78K shares, representing 1.80% of shares outstanding, with 30.07% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
New Enterprise Associates (NEA)
Wilson (John Robert)
Blue Owl Capital Holdings LP
Aisling Capital Management LP
Vera (Juan F. M.D.)
Geode Capital Management, L.L.C.
Two Sigma Investments, LP
Osaic Holdings, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2026-01-09The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Marker Therapeutics Inc is 2.65, ranking 216 out of 396 in the Biotechnology & Medical Research industry. The company's beta value is 1.44. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Marker Therapeutics Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.
Score
Beta vs S&P 500 index
1.44
VaR
+9.23%
240-Day Maximum Drawdown
+59.28%
240-Day Volatility
+126.76%
Return
Best Daily Return
60 days
+17.74%
120 days
+17.74%
5 years
+51.27%
Worst Daily Return
60 days
-8.79%
120 days
-20.63%
5 years
-93.67%
Sharpe Ratio
60 days
+3.50
120 days
+0.82
5 years
+0.36
Risk Assessment
Maximum Drawdown
240 days
+59.28%
3 years
+90.31%
5 years
+98.01%
Return-to-Drawdown Ratio
240 days
+0.06
3 years
-0.02
5 years
-0.19
Skewness
240 days
+1.14
3 years
+1.12
5 years
-0.56
Volatility
Realised Volatility
240 days
+126.76%
5 years
+127.26%
Standardised True Range
240 days
+6.65%
5 years
+24.87%
Downside Risk-Adjusted Return
120 days
+146.21%
240 days
+146.21%
Maximum Daily Upside Volatility
60 days
+76.34%
Maximum Daily Downside Volatility
60 days
+52.15%
Liquidity
Average Turnover Rate
60 days
+23.40%
120 days
+12.24%
5 years
--
Turnover Deviation
20 days
+629.42%
60 days
+564.17%
120 days
+247.39%
Peer Comparison
Biotechnology & Medical Research
Marker Therapeutics Inc
MRKR
7.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.49 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IDEAYA Biosciences Inc
IDYA
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Marker Therapeutics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Marker Therapeutics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Marker Therapeutics Inc’s performance and outlook.
How do we generate the financial health score of Marker Therapeutics Inc?
To generate the financial health score of Marker Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Marker Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Marker Therapeutics Inc.
How do we generate the company valuation score of Marker Therapeutics Inc?
To generate the company valuation score of Marker Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Marker Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Marker Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Marker Therapeutics Inc.
How do we generate the earnings forecast score of Marker Therapeutics Inc?
To calculate the earnings forecast score of Marker Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Marker Therapeutics Inc’s future.
How do we generate the price momentum score of Marker Therapeutics Inc?
When generating the price momentum score for Marker Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Marker Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Marker Therapeutics Inc.
How do we generate the institutional confidence score of Marker Therapeutics Inc?
To generate the institutional confidence score of Marker Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Marker Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Marker Therapeutics Inc.
How do we generate the risk management score of Marker Therapeutics Inc?
To assess the risk management score of Marker Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Marker Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Marker Therapeutics Inc.
